Concepedia

Joseph Fiore

JF

Statistics

Publications

18

Citations

2.5K

H-Index

15

Active since

1988

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Massachusetts General Hospital

Dana-Farber Cancer Institute

The Barbara Ann Karmanos Cancer Institute

South Texas Accelerated Research Therapeutics

Joseph Fiore is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and pharmacology.

Publications per year

1988–2025

18

Publications

18

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology · 2016 · 1.4K citations

, , +13

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Hossein Borghaei, Corey J. Langer, Shirish M. Gadgeel et al. · Journal of Thoracic Oncology · 2018 · 197 citations

, , +12

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia VanDam Sequist et al. · Journal of Thoracic Oncology · 2018 · 183 citations

, , +13

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Patrick M. Forde, Jonathan Spicer, Mariano Provencio et al. · New England Journal of Medicine · 2025 · 160 citations

, , +15

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

Patrick M. Forde, Jonathan Spicer, Shun Lü et al. · Cancer Research · 2021 · 99 citations

, , +15

1–5 of 18